Compile Data Set for Download or QSAR
Report error Found 45 of ki for UniProtKB: P35222
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682700(US20240208940, Example 44)
Affinity DataKi: <2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682673(US20240208940, Example 17)
Affinity DataKi: <2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682693(US20240208940, Example 37)
Affinity DataKi: <2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682701(US20240208940, Example 45)
Affinity DataKi: <4.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682675(US20240208940, Example 19)
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682692(US20240208940, Example 36)
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682668(US20240208940, Example 12)
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682667(US20240208940, Example 11)
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682691(US20240208940, Example 35)
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682687(US20240208940, Example 31)
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682686(US20240208940, Example 30)
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682690(US20240208940, Example 34)
Affinity DataKi: <1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682689(US20240208940, Example 33)
Affinity DataKi: <1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682669(US20240208940, Example 13)
Affinity DataKi: <1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682670(US20240208940, Example 14)
Affinity DataKi: <1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682688(US20240208940, Example 32)
Affinity DataKi: <1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682695(US20240208940, Example 39)
Affinity DataKi:  1.40E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682684(US20240208940, Example 28)
Affinity DataKi: <2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682674(US20240208940, Example 18)
Affinity DataKi: <2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682671(US20240208940, Example 15)
Affinity DataKi: <2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682666(US20240208940, Example 10)
Affinity DataKi: <2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682665(US20240208940, Example 9)
Affinity DataKi: <2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682694(US20240208940, Example 38)
Affinity DataKi: <2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682697(US20240208940, Example 41)
Affinity DataKi: <2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682683(US20240208940, Example 27)
Affinity DataKi: <3.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682661(US20240208940, Example 5)
Affinity DataKi: <4.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682698(US20240208940, Example 42)
Affinity DataKi: <5.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682679(US20240208940, Example 23)
Affinity DataKi: <5.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682685(US20240208940, Example 29)
Affinity DataKi: <5.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682657(US20240208940, Example 1)
Affinity DataKi: <5.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682678(US20240208940, Example 22)
Affinity DataKi: <5.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682677(US20240208940, Example 21)
Affinity DataKi: <5.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682672(US20240208940, Example 16)
Affinity DataKi: <5.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682664(US20240208940, Example 8)
Affinity DataKi: <5.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682681(US20240208940, Example 25)
Affinity DataKi: <6.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682663(US20240208940, Example 7)
Affinity DataKi: <6.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682699(US20240208940, Example 43)
Affinity DataKi:  8.10E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682658(US20240208940, Example 2)
Affinity DataKi: >8.40E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682659(US20240208940, Example 3)
Affinity DataKi: >8.40E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682660(US20240208940, Example 4)
Affinity DataKi: >8.40E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682662(US20240208940, Example 6)
Affinity DataKi: >8.40E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682696(US20240208940, Example 40)
Affinity DataKi:  8.40E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682676(US20240208940, Example 20)
Affinity DataKi:  8.40E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682680(US20240208940, Example 24)
Affinity DataKi:  8.40E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682682(US20240208940, Example 26)
Affinity DataKi: <1.00E+5nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent